Ciltacabtagene Autoleucel

Share page

Scientific Name Ciltacabtagene Autoleucel
Brand Name CARVYKTI
Risk
  • Potential risk of T-cell malignancy associated with the use of chimeric antigen receptor (CAR) T cell Immunotherapies
  • Secondary malignancies of T-cell origin, including chimeric antigen receptor (CAR)- positive malignancies, have been reported within weeks and up to several years following treatment of haematological malignancies with a BCMA- or CD19-directed CAR T-cell therapy.
  • Patients should be monitored life-long for secondary malignancies.
Educational Materials for Healthcare Professionals
Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals
Safety Communication for Healthcare Professionals
Educational Materials for Patients
هل استفدت من ما هو مقدم في هذه الصفحة؟
0 من الزوار ردوا بنعم من أصل0 مشاركة
السبب
السبب